ReviewFrontiers in pediatrics2026
Xingpi Yanger Granule combined with conventional medication for the treatment of nocturnal enuresis: a systematic review and meta-analysis of randomized controlled trials.
Review in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This systematic review aims to determine the clinical efficacy and safety of Xingpi Yanger Granule (XPYEG) in combination with conventional medication for the treatment of Nocturnal Enuresis based on existing data. Methods: A systematic search was conducted across the China National Knowledge Infrastructure (CNKI), Wanfang Data, China Biomedical Literature Database (CBM), VIP, PubMed, Embase, Cochrane Library, and Web of Science databases to identify relevant RCTs on the auxiliary treatment of NE in children using XPYEG from the inception of each database up to August 2025. The risk of bias in the included RCTs was assessed using the Cochrane Risk of Bias tool (ROB2). Meta-analysis was performed using Review Manager, and the sensitivity analysis was conducted using Stata 18 software. The quality of evidence was evaluated with the GRADE approach. Furthermore, Trial Sequential Analysis (TSA) was employed to determine the required sample size and to verify the reliability of the findings. The review protocol was registered and published on PROSPERO (CRD420251156842). Results: This study included 12 RCTs involving 1,138 patients. Compared with conventional therapy alone, the combination of XPYEG significantly improves core symptoms, which is clinically significant. Core Symptom and Functional Outcomes: Compared with the control group, adjunctive XPYEG therapy resulted in a notable reduction in the frequency of NE [MD = 1.55, 95% CI (0.66, 2.43), Conclusion: Xingpi Yanger Granule may improve overall response, moderately reduce urinary frequency, and increase bladder capacity, while also lowering the recurrence rate and the incidence of adverse events. However, given that the evidence is limited in scope and rated as low to moderate quality, current conclusions should be interpreted with caution. Well-designed, large-scale, multicenter randomized controlled trials are needed to validate these potential benefits. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/, PROSPERO CRD420251156842.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.